Evercore ISI on Vera Therapeutics (VERA): 'buying opportunity'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cantor Fitzgerald Reiterates Overweight Rating on Vera Therapeutics (VERA)
February 18, 2025 6:46 AM ESTCantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating and $107.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst commented, Overall, we see a compelling outlook for VERA. We continue to point to the data generated to date for atacicept (dual APRIL/BAFF inhibitor) in... More
Vera Therapeutics Inc. (VERA) Weakness Tied to Rival Drug, Analyst Says
February 14, 2025 11:12 AM ESTVera Therapeutics Inc. (NASDAQ: VERA) Weakness Tied to Rival Drug, Analyst Says
VERA -17%Analyst Liisa Bayko said, "Otsuka provided an update on sibeprelimab overnight (as part of 2024 earnings). Recall, sibeprenlimab is expected to be the key competitor to Veras atacicept in... More